康柏西普对糖尿病性黄斑水肿的疗效评价

发布时间：2018-05-08 05:35

  本文选题：糖尿病性黄斑水肿 + 康柏西普　； 参考：《上海交通大学学报(医学版)》2017年05期

【摘要】：目的·评价玻璃体腔内注射抗血管内皮生长因子(VEGF)药物康柏西普对治疗糖尿病性黄斑水肿(DME)的临床效果。方法·选取DME(炎症型)患者11例17眼,每月行1次康柏西普玻璃体腔内注射,首次治疗之后按需治疗。治疗结束后随诊6个月以上,比较治疗前后患者的最佳矫正视力(BCVA)、中央视网膜厚度(CRT)、DME消退率及眼底荧光血管造影检查(FFA)结果。结果·随访时间为7~29个月,平均(12±7)个月。注射针数1~10针,平均针数为(4±3)针。DME患者注药后BCVA明显提高(t=7.306,P=0.001),CRT下降显著(t=5.272,P=0.000),差异有统计学意义。DME总消退率为76.5%。结论·玻璃体腔内注射抗VEGF药物康柏西普,可明显改善DME患者的视力,明显消退黄斑水肿症状。
[Abstract]:Objective to evaluate the effect of intravitreal injection of anti vascular endothelial growth factor (VEGF) on diabetic macular edema (DM). Methods 11 cases (17 eyes) of DME (inflammatory type) were treated by intravitreal injection once a month. The best corrected visual acuity (BCVA), central retinal thickness (CRT), DME regression rate and fundus fluorescein angiography (FFA) were compared before and after treatment. Results the follow-up time was 7 ~ 29 months (mean 12 卤7) months. The average number of injections was 4 卤3). The BCVA of the patients with DME was significantly higher than that of the control group (P < 0.01). The decrease of BCVA was significant (P < 0.01). The difference was statistically significant. The total regression rate of DME was 76.5%. ConclusionIntravitreal injection of VEGF can significantly improve the visual acuity of patients with DME and attenuate the symptoms of macular edema.
【作者单位】： 上海交通大学医学院附属仁济医院眼科;上海市浦东新区陆家嘴社区卫生服务中心眼科;上海市浦东新区公利医院眼科;上海市浦东新区潍坊社区卫生中心眼科;
【基金】：上海市浦东新区卫生局卫生(计生)科技项目(PW2013D-1) 上海市卫生和计划生育委员会面上项目(M20140513)~~
【分类号】：R587.2;R774
，

本文编号：1860159